CJC-1295 (No DAC)
A modified GHRH analogue without Drug Affinity Complex, commonly used in research examining pulsatile growth hormone-releasing pathway activity. Its shorter duration of action makes it well-suited for studying natural GH secretion patterns and acute receptor responses.
CJC-1295 (No DAC) Overview
CJC-1295 (No DAC), also commonly referred to as Modified GRF (1-29), is a GHRH-based peptide analogue studied for its activity at the growth hormone-releasing hormone receptor. Unlike the DAC version, it does not include the drug affinity complex used for albumin binding, so it is generally used in research examining shorter-duration receptor activity and pulsatile signaling behavior.
Mechanism of Action & Applications
CJC-1295 (No DAC) is studied for agonist activity at the GHRH receptor. In laboratory research, this makes it useful for examining pituitary signaling, pulsatile growth hormone release dynamics, receptor activation patterns, and the differences between shorter-acting GHRH analogues and longer-acting albumin-binding designs. It is commonly used in studies involving GHRH receptor biology, endocrine signaling, peptide half-life comparisons, and growth hormone pathway research.
Research History
CJC-1295 (No DAC) developed from efforts to modify the native GHRH(1-29) sequence to improve receptor activity and stability while preserving a shorter-acting signaling profile than DAC-linked analogues. In published and reference chemistry sources, it is widely associated with Modified GRF (1-29), which is distinct from CJC-1295 with DAC.
Chemical Information
- CAS Number
- 863288-34-0
- Molecular Formula
- C152H252N44O42
- Molecular Weight
- 3,367.9 g/mol
- PubChem ID
- 91972073
For research use only. Not for human or veterinary use. Detailed storage guidelines →
Often Paired With
Researchers who buy CJC-1295 (No DAC) commonly stock these alongside it.
Researcher Reviews
%2010MG.png)